Tag Archive for: Lytix Biopharma

Lytix Biopharma presents third quarter 2023 results

Oslo, 09 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today releases its third quarter 2023 results. Dr. Øystein Rekdal, Chief Executive Officer of Lytix Biopharma, commented: “We continue our efforts to demonstrate the clinical benefits of LTX-315 in patients with skin cancers. First and foremost, we are […]

Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from ’SkatteFUNN’

Oslo, 17 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that the Research Council of Norway has approved Lytix’s application for up to NOK14.3m (US$1.3m) of non-dilutive financial support from the ‘SkatteFUNN’ R&D tax incentive scheme for a project in respect of its lead […]

Neoadjuvant study with LTX-315 in early-stage melanoma patients to be presented at the 15th Nordic melanoma meeting

Oslo, 9 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that Dr Henrik Jespersen, Head of Melanoma Oncology at Oslo University Hospital, will give a presentation of the NeoLIPA trial with LTX-315 at the 15th Nordic Melanoma Meeting (Reykjavik, 11-13 October 2023). The title […]

Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial

Oslo, 29 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that it has completed recruitment of 20 patients in the ATLAS-IT-05 trial – a trial evaluating LTX-315, Lytix’s lead drug candidate. Read more…..